Artificial Intelligence in Radiation Oncology: Evidence and Oversight
AI tools are being studied across the radiotherapy workflow. Reviews and working-group assessments describe potential roles and implementation challenges, while clinical benefit must be evaluated tool by tool.
AI tools are being studied across the radiotherapy workflow. Reviews and working-group assessments describe potential roles and implementation challenges, while clinical benefit must be evaluated tool by tool.
AI spans a workflow, not a single clinical intervention
Radiation therapy involves multiple connected steps, from imaging and contouring through treatment planning, quality assurance, and delivery. AI research covers tools across this workflow, but performance at one step does not validate a different use. A model that supports segmentation, for example, raises different safety and validation questions from a system that generates or optimizes a treatment plan.
The 2025 comprehensive review surveys applications across the radiotherapy pathway and discusses implementation, regulation, clinical trials, and ethical integration. It is a broad secondary source. The NRG Oncology working-group assessment focuses more specifically on AI-based automatic treatment planning in radiation therapy clinical trials. Together, they help define use cases and challenges; neither should be presented as a randomized demonstration of improved patient outcomes.
Automatic treatment planning in trials has operational promise
The NRG assessment describes the potential for AI-supported automatic planning to improve plan quality and streamline planning processes in clinical trials. It also identifies integration challenges and outlines short-term actions and future directions. This is a working-group assessment of the state of the field, not a head-to-head clinical trial proving that an AI plan improves local control, survival, toxicity, or quality of life.
Trial planning is a particularly important context because protocol consistency, plan quality, and reproducibility affect how evidence is generated. Yet any efficiency gain must be weighed against the need for protocol compliance, independent checking, and transparent documentation. A system that accelerates planning still needs to demonstrate that its outputs meet clinical and trial-specific constraints.
Validation should match the intended use
A credible evaluation begins with a clearly defined task, intended user, patient population, and clinical setting. Technical performance on a curated dataset is not the same as performance in routine practice. Validation should include representative data, external sites, relevant subgroups, failure cases, and workflow conditions. A model’s inputs, outputs, update behavior, and human review responsibilities should be explicit.
The cited reviews describe a wide range of potential applications and emphasize safe integration. They do not provide one shared validation standard or a single performance threshold that applies to all tools. The level of evidence needed depends on the potential consequences of error and on whether the system is advisory, automates a bounded task, or influences a treatment plan.
Human oversight and governance remain necessary
AI tools do not remove professional responsibility. Clinical teams need to know what a system is designed to do, what it cannot do, how uncertainty is handled, and when a user should override or reject its output. Governance should cover version control, auditability, cybersecurity, data provenance, monitoring after deployment, and clear escalation paths when outputs appear unsafe or inconsistent.
The comprehensive review notes regulatory and guideline considerations, while the NRG assessment discusses integration challenges in trials. These topics signal that technical performance alone is insufficient. Local governance must also address accountability, clinician training, protocol approval, and reporting of tool-related deviations.
Efficiency claims need patient-relevant confirmation
Streamlining a workflow or reducing manual workload can be valuable, but it is an intermediate outcome. A claim of better patient care needs evidence that is appropriate to the clinical question, such as plan quality, treatment delivery accuracy, toxicity, or another prespecified endpoint. Efficiency should not be converted into a claim of improved survival or reduced harm unless those outcomes were actually evaluated.
The two cited sources are reviews and a working-group assessment, not randomized trials of an AI-enabled treatment strategy. They support continued evaluation and structured implementation, while leaving comparative patient-outcome questions open. Evidence summaries should identify this distinction explicitly.
A practical checklist for reading AI evidence
Ask what exact task is automated; whether the data represent the intended setting; how performance was tested outside the development sample; whether results differ across subgroups; and how failures are detected. For planning tools, examine protocol constraints, clinician review, plan acceptance, and downstream delivery. For any product, check regulatory status and the institution’s approval pathway rather than assuming that publication equals authorization.
Also distinguish a review of possible applications from prospective evaluation of a named system. AI methods and software can change quickly, so a result should be tied to the model version, data, and workflow actually studied. Without those details, a general claim of “AI improves radiation therapy” is too broad to guide a responsible decision.
Where the evidence goes next
Future work should define clinically meaningful endpoints, include external validation, report failures and human interventions, and examine whether benefits persist across institutions. The NRG assessment points toward personalized algorithms and integration into routine practice as future directions, not settled outcomes. Prospective studies and post-deployment monitoring can help close the gap between algorithmic performance and safe clinical utility.
For now, the sources support a measured view: AI has potential roles across radiation therapy, but each use requires task-specific evidence, governance, and human oversight. This is a professional education brief, not individual medical advice or a recommendation to use a particular product.